目的 观察钠-葡萄糖协同转运蛋白2抑制剂(SGLT-2i)卡格列净对超重及肥胖的2型糖尿病(T2DM)患者骨转换标志物的影响。 方法 选取2019年10月9日至2020年12月28日住院的42例超重及肥胖T2DM患者，随机分为实验组(n＝18)和对照组(n＝24)，实验组应用卡格列净联合其他类降糖药物，对照组应用非SGLT-2i类降糖药物，比较两组治疗前及治疗24周后血清Ⅰ型胶原N端前肽(PINP)及Ⅰ型胶原C末端肽交联(β-CTX)的变化。 结果 治疗后两组比较，PINP无显著差异，实验组β-CTX水平低于对照组(P<0.05)。 结论 应用卡格列净对超重及肥胖T2DM患者骨形成无明显影响，可能对骨吸收有一定抑制作用。 Objective To observe the effects of sodium-glucose cotransporter 2 inhibitor (SGLT-2i) Canagliflozin on bone turnover markers in overweight and obese patients with type 2 diabetes (T2DM). Methods A total of 42 overweight and obese T2DM patients (BMI≥25 kg/m2) who were hospitalized in our hospital from October 9, 2019, to December 28, 2020, were selected and randomly divided into experimental group (n=18) and control group (n=24). The experimental group was treated with Canagliflozin, while the control group was treated with non-SGLT-2 i. The changes of serum PINP and β-CTX levels were compared between the two groups before and after treatment for 24 weeks. Results After treatment, there was no significant difference in PINP between the two groups, while β-CTX was lower in the experimental group than that in the control group. Conclusions Canagliflozin has no significant effect on bone formation but may inhibit bone resorption in overweight and obese T2DM patients.
Effect of SGLT-2 inhibitor on bone turnover markers in overweight and obese patients with type 2 diabetes
Objective To observe the effects of sodium-glucose cotransporter 2 inhibitor (SGLT-2i) Canagliflozin on bone turnover markers in overweight and obese patients with type 2 diabetes (T2DM). Methods A total of 42 overweight and obese T2DM patients (BMI≥25 kg/m2) who were hospitalized in our hospital from October 9, 2019, to December 28, 2020, were selected and randomly divided into experimental group (n=18) and control group (n=24). The experimental group was treated with Canagliflozin, while the control group was treated with non-SGLT-2 i. The changes of serum PINP and β-CTX levels were compared between the two groups before and after treatment for 24 weeks. Results After treatment, there was no significant difference in PINP between the two groups, while β-CTX was lower in the experimental group than that in the control group. Conclusions Canagliflozin has no significant effect on bone formation but may inhibit bone resorption in overweight and obese T2DM patients.
Type 2 diabetesSGLT-2 inhibitorBone metabolismPINPβ-CTX
万方数据
